Skip to main content
. 2017 Jun 12;8(30):50002–50014. doi: 10.18632/oncotarget.18442

Figure 4. ERβ agonists attenuate NF-κB pathway activation.

Figure 4

(A) ES2, SKOV3, and SKOV3-TR cells were transfected with NF-κB-luc reporter plasmid and grown for 24 h. Then, cells were treated with ERβ agonists and reporter activity was measured after 24 h. ES2 (B) and SKOV3 (C) cells were treated with Liq or S-equol (100 μM) for 24 h, and the expression status of NF-κB target genes was analyzed by using RT-qPCR. (D) ES2 cell lysates were used in pull-down assays using GST or ERβ-GST, and interaction of ERβ with p65 was analyzed by Western blotting. (E) ES2-ERβ-FLAG cell lysates were subjected to immunoprecipitation with IgG or FLAG antibodies and the interaction of ERβ with p65 was confirmed by Western blotting. (F) SKOV3 cells were transduced with empty vector or ERβ-FLAG expression vector and the expression of NF-κB target genes was analyzed by using RT-qPCR. Data are represented as mean ± SE. * p<0.05; ** p<0.01; *** p<0.001.